Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Blood (2020) 136 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2020-143816

Published: 2020

Journal Articles

ATG and Post-Transplant Cyclophosphamide Do Not Abrogate the Inferior Outcome Risk Conferred By HLA-Α and HLA-B Mismatched Unrelated Donors

Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Remberger Mats, PhD, Carol Chen, Ivan Pasic, MDPhD, Zeyad Al-Shaibani, MD, Wilson Lam, MD, Arjun Law, MD, Armin Gerbitz, MDPhD, Auro Viswabandya, MDDM, Jeffrey H. Lipton, MD PhD, Dennis Dong Hwan Kim, MD PhD, Rajat Kumar, MD, Fotios Michelis, MD PhD, Jonas Mattsson, MD

Blood (2020) 136 (Supplement 1): 31.

https://doi.org/10.1182/blood-2020-139736

Published: 2020

Journal Articles

Multicenter, Retrospective Evaluation of Therapeutic Efficacy of Ruxolitinib for Chronic Gvhd Treatment

Jennifer White, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA, Swe Mar Linn, MBBS, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Omar Abduljalil, Arjun Law, MD, Dennis Dong Hwan Kim, MD

Blood (2020) 136 (Supplement 1): 45–47.

https://doi.org/10.1182/blood-2020-136164

Published: 2020

Journal Articles

CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study

Claire Andrews, Taylor Young, Eshetu G Atenafu, M.Sc., P.Stat, Sarit E Assouline, MD MSc, Joseph M Brandwein, MD, Steven M Chan, MD PhD, Signy Chow, MD FRCP(C), Dina Khalaf, BSc, MSc, MD, Vikas Gupta, MD FRCP, FRCPath, Dennis Dong Hwan Kim, MD, Dawn Maze, MDFRCPC,MSc, Mark D. Minden, Caroline J McNamara, MBBS, Tracy Murphy, MDFRCP,FRCPath, David Sanford, MD, Aaron D Schimmer, MD PhD, Andre C. Schuh, Karen W.L. Yee, MD, Hassan Sibai, MBBS

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-142990

Published: 2020

Journal Articles

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Dennis Dong Hwan Kim, MD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Taehyung Kim, MSc, Eshetu G Atenafu, M.Sc., P.Stat, Lynn Savoie, MD, Isabelle Bence-Bruckler, MD, Donna L. Forrest, MD, Lambert Busque, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Mary-Margaret Keating, MD FRCPC, Elena Liew, MDBSc,FRCPC, Kristjan Paulson, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Pierre Laneuville, MD FRCPC, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2020) 136 (Supplement 1): 54–55.

https://doi.org/10.1182/blood-2020-136163

Published: 2020

Journal Articles

Efficacy and Cost Analysis of Eltrombopag in Thrombocytopenia and Poor Graft Function Post Allogeneic Hematopoietic Cell Transplantation in a Canadian Centre - a Prospective Observational Study

RAM V Nampoothiri, MDDM MRCP (UK), Lina Ho, Cassandra McEwan, Ivan Pasic, MDPhD, Zeyad Al-Shaibani, MD, Wilson Lam, MD, Arjun Law, MD, Fotios Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Armin Gerbitz, MDPhD, Auro Viswabandya, MD, Jeffrey H. Lipton, MD PhD, Jonas Mattsson, MD, Rajat Kumar, MD

Blood (2020) 136 (Supplement 1): 18.

https://doi.org/10.1182/blood-2020-142302

Published: 2020

Journal Articles

Allogeneic Transplant Can Abrogate the Relapse Risk in the Patients with Detectable Measureable Residual Disease By Multicolor Flow-Cytometry at the Time of Assessment of Acute Myeloid Leukemia Patients in First Remission

Muhned Alhumaid, MD, Georgina S. Daher-Reyes, MD, Arjun Law, MD, Auro Viswabandya, MD, Armin Gerbitz, MD, Fotios Michelis, MD PhD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Jeffrey H. Lipton, MD PhD, Jonas Mattson, MD PhD, Ivan Pasic, MDPhD, Rajat Kumar, MD, Wilson Lam, MD, Zeyad Al-Shaibani, MD, Hassan Sibai, MBBS, Dennis Dong Hwan Kim, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-136122

Published: 2020

Journal Articles

Increased Risk of Secondary Malignancy Associated with the Use of Azathioprine for Chronic Graft-Versus-Host Disease Treatment

Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Ivan Pasic, MDPhD, Zeyad Al-Shaibani, MD, Wilson Lam, MD, Arjun Law, MD, Armin Gerbitz, MDPhD, Auro Viswabandya, MDDM, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Fotios Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-138927

Published: 2020

Journal Articles

Donor Selection May Predict Improved Survival Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia - Experience from a Tertiary Care Centre

RAM V Nampoothiri, MDDM MRCP (UK), Carol Chen, Zeyad Al-Shaibani, MD, Ivan Pasic, MDPhD, Arjun Law, MD, Wilson Lam, MD, Fotios Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Armin Gerbitz, MDPhD, Auro Viswabandya, MD, Jeffrey H. Lipton, MD PhD, Jonas Mattsson, MD, Rajat Kumar, MD, Santhosh Thyagu, MDDM

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-142982

Published: 2020

Journal Articles

Single Centre, Retrospective Study to Evaluate Treatment Outcomes Following Tyrosine Kinase Inhibitor for Chronic Gvhd Treatment Including Ruxolitinib, Ibrutinib and Imatinib

Swe Mar Linn, MBBS, Omar Abduljalil, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, RAM V Nampoothiri, MDDM MRCP (UK), Ivan Pasic, MDPhD, Zeyad Al-Shaibani, MD, Wilson Lam, MD, Arjun Law, MD, Fotios Michelis, MD PhD, Armin Gerbitz, MDPhD, Auro Viswabandya, MD, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Jonas Mattson, MD PhD, Dennis Dong Hwan Kim, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-142182

Published: 2020

Journal Articles

BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

Dennis Dong Hwan Kim, MD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Taehyung Kim, MSc, Eshetu G Atenafu, M.Sc., P.Stat, Donna L. Forrest, MD, Lynn Savoie, MD, Isabelle Bence-Bruckler, MD, Mary-Margaret Keating, MD FRCPC, Lambert Busque, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Kristjan Paulson, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Pierre Laneuville, MD FRCPC, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-136162

Published: 2020

Journal Articles

Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Harboring DNMT3A/TET2/ASXL1 Mutation

Muhned Alhumaid, MD, Georgina S. Daher-Reyes, MD, Aaron D Schimmer, MD PhD, Andre C. Schuh, Anne Tierens, MD PhD, Caroline J McNamara, MBBS, Dawn Maze, MDFRCPC,MSc, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Karen W.L. Yee, MD, Mark D. Minden, Steven M Chan, MD PhD, Tracy Murphy, MDFRCP,FRCPath, Vikas Gupta, MD FRCP, FRCPath, Dennis Dong Hwan Kim, MD, Hassan Sibai, MBBS

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-138862

Published: 2020

Journal Articles

Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt

Georgina S. Daher-Reyes, MD, Isabelle Bence-Bruckler, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Mary-Margaret Keating, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 1653.

https://doi.org/10.1182/blood-2019-131599

Published: 2019

Journal Articles

Risk Factors for Primary and Secondary Graft Failure in Allogenic Hematopoietic Cell Transplantation: A Single Center Study

Zeyad Al-Shaibani, MD, Eshrak AL-Shaibani, MD, Mats Remberger, PhD, Wilson Lam, MD, Arjun Law, MD, Fotios V. Michelis, MD PhD, Auro Viswabandya, MD, Dennis Dong Hwan Kim, MD, Jeffrey H. Lipton, MD PhD, Jonas Mattson, MD PhD, Rajat Kumar, MD

Blood (2019) 134 (Supplement_1): 2046.

https://doi.org/10.1182/blood-2019-124208

Published: 2019

Journal Articles

BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

Blood (2019) 134 (Supplement_1): 2933.

https://doi.org/10.1182/blood-2019-131454

Published: 2019

Journal Articles

Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT

Maria Queralt Salas, MD, Arjun Law, MDDM, Wilson Lam, MD, Fotios V. Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, David Loach, MD, Zeyad Al-Shaibani, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Auro Viswabandya, MDDM

Blood (2019) 134 (Supplement_1): 3344.

https://doi.org/10.1182/blood-2019-128639

Published: 2019

Journal Articles

Pilot Study on Frailty and Functionality on Routine Clinical Assessment in Allogeneichematopoietic Cell Transplantation to Predict Outcomes

Maria Queralt Salas, MD, Eshetu G Atenafu, M.Sc., P.Stat, Ora Bascom, Allo-HSCT Coordinator, Leeann Wilson, RN, BSc, BSc N(HON), CON(c), Arjun Law, MDDM, Wilson Lam, MD, David Loach, MD, Zeyad Al-Shaibani, Fotios V. Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Jeffrey H. Lipton, MD PhD, Auro Viswabandya, MDDM, Jonas Mattsson, MD, Alibhai M.H. Shabbir, MD, Rajat Kumar, MD

Blood (2019) 134 (Supplement_1): 380.

https://doi.org/10.1182/blood-2019-126071

Published: 2019

Journal Articles

No Impact of Donor's Age-Related Clonal Hematopoiesis (ARCH) Observed on Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Result from Bar-Coded Error Corrected Sequencing in 33 Gene Mutations on 372 Pairs of Donor and Recipient

Kyoung Ha Kim, MD PhD, Taehyung Kim, MSc, Jae-Sook Ahn, MD PhD, Zeyad Al-Shaibani, Arjun Law, MD, Wilson Lam, MD, Fotios V. Michelis, MD PhD, Auro Viswabandya, MDDM, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Zhaolei Zhang, PhD, Tamir Biezuner, PhD, Liran I. Shlush, MD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 4514.

https://doi.org/10.1182/blood-2019-129497

Published: 2019

Journal Articles

Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning

Maria Queralt Salas, MD, Shiyi Chen, Wilson Lam, MD, David Loach, MD, Fotios V. Michelis, MD PhD, Zeyad Al-Shaibani, Dennis Dong Hwan Kim, MD PhD, Jeffrey H. Lipton, MD PhD, Auro Viswabandya, MDDM, Rajat Kumar, MD, Jonas Mattsson, MD, Arjun Law, MDDM

Blood (2019) 134 (Supplement_1): 4590.

https://doi.org/10.1182/blood-2019-126236

Published: 2019

Journal Articles

Improved Gvhd Free, Relapse Free Survival Using Dual T-Cell Depletion with ATG and Ptcy in Matched Unrelated Donor RIC Allo-HSCT

Maria Queralt Salas, MD, Wilson Lam, MD, Arjun Law, MDDM, Fotios V. Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Zeyad Al-Shaibani, David Loach, MD, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Auro Viswabandya, MDDM

Blood (2019) 134 (Supplement_1): 4594.

https://doi.org/10.1182/blood-2019-128720

Published: 2019

NARROW

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

ATG and Post-Transplant Cyclophosphamide Do Not Abrogate the Inferior Outcome Risk Conferred By HLA-Α and HLA-B Mismatched Unrelated Donors

Multicenter, Retrospective Evaluation of Therapeutic Efficacy of Ruxolitinib for Chronic Gvhd Treatment

CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Efficacy and Cost Analysis of Eltrombopag in Thrombocytopenia and Poor Graft Function Post Allogeneic Hematopoietic Cell Transplantation in a Canadian Centre - a Prospective Observational Study

Allogeneic Transplant Can Abrogate the Relapse Risk in the Patients with Detectable Measureable Residual Disease By Multicolor Flow-Cytometry at the Time of Assessment of Acute Myeloid Leukemia Patients in First Remission

Increased Risk of Secondary Malignancy Associated with the Use of Azathioprine for Chronic Graft-Versus-Host Disease Treatment

Donor Selection May Predict Improved Survival Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia - Experience from a Tertiary Care Centre

Single Centre, Retrospective Study to Evaluate Treatment Outcomes Following Tyrosine Kinase Inhibitor for Chronic Gvhd Treatment Including Ruxolitinib, Ibrutinib and Imatinib

BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Harboring DNMT3A/TET2/ASXL1 Mutation

Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt

Risk Factors for Primary and Secondary Graft Failure in Allogenic Hematopoietic Cell Transplantation: A Single Center Study

BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT

Pilot Study on Frailty and Functionality on Routine Clinical Assessment in Allogeneichematopoietic Cell Transplantation to Predict Outcomes

No Impact of Donor's Age-Related Clonal Hematopoiesis (ARCH) Observed on Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Result from Bar-Coded Error Corrected Sequencing in 33 Gene Mutations on 372 Pairs of Donor and Recipient

Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning

Improved Gvhd Free, Relapse Free Survival Using Dual T-Cell Depletion with ATG and Ptcy in Matched Unrelated Donor RIC Allo-HSCT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only